What does a reportable test actually cost you?
Ask most laboratories what a test costs and they will quote the reagent price. But a released result is the sum of many things, and the parts nobody counts are usually the ones eating the margin.
When you price a menu without knowing what each test costs, you are setting prices in the dark. Some tests carry the lab, others quietly drain it, and you cannot tell which is which.
Pricing a test menu is one of the most consequential things a laboratory does, and it is usually done in the dark. Without a true cost for each test, the price is set by what the lab charged last year, what the competitor down the road charges, or a markup applied to a reagent figure that was never the real cost. The result is a menu where some tests are comfortably profitable, others are run at a loss, and nobody can say which is which. The profitable tests quietly subsidise the loss-makers, the overall margin looks acceptable until volumes shift, and the lab discovers its mistakes only when a change in mix tips it into the red.
Pricing well does not require charging more. It requires knowing what each test costs, so the price sits a deliberate distance above that cost rather than a hopeful one. A menu priced on real cost holds the margin the lab intends, test by test, instead of leaving it to luck.
The trouble with pricing on guesswork is that it fails silently. A test priced below its true cost does not announce the loss, it just produces a result and a small shortfall, repeated every time it runs. As long as the profitable tests carry enough volume, the lab stays afloat and the loss-makers stay hidden. Then the mix shifts, a payer contract pushes more of the loss-making test through the lab, or a profitable one falls away, and the subsidy that was holding everything up disappears. Suddenly the margin collapses, and the cause is a pricing decision made years ago on a number nobody checked.
Because the prices were never tied to real cost, the lab cannot even diagnose the problem cleanly. It knows margin is down but not which prices are wrong, so it raises everything a little, annoys its customers, and still does not fix the underlying mismatch.
Pricing on real cost requires a real cost for every test on the menu, kept current as conditions change. That is precisely the thing labs find hard to produce. Building a true cost per test by hand, across a menu of dozens or hundreds of tests, and keeping every figure up to date as reagent prices move, is work nobody can sustain. So the lab prices on the figures it can get, which are the incomplete ones, and the menu drifts further from reality with every reagent price change it does not capture.
A price is only as good as the cost beneath it. Set prices on a number you have never measured and you are not pricing, you are hoping. The lab that knows its cost prices on purpose.
Veona Cost Per Reportable Test gives every test a true, current cost, consolidated from reagents, controls, wastage and overheads, drawn from the books the lab already runs. With that cost in hand, pricing stops being a guess. You can see the real margin on every test, set a price a deliberate distance above its true cost, and know which tests are carrying the lab and which were quietly draining it. Because the cost is current, the price can stay current too: when a reagent price rises and erodes a margin, you see it and reprice on a real number rather than discovering the loss later.
This also turns a negotiation into a conversation you can win. When a payer or a corporate client pushes on price, you can hold the line knowing exactly where your cost sits and what margin a given price leaves. The same true cost that lets you set prices lets you defend them, in a tender or across a table. We cover that costing-as-leverage idea in cost intelligence for a profitable lab, and the variance work that keeps cost honest in spotting the high-variance tests.
For a Nigerian laboratory, pricing is not a once-a-year exercise, it is a moving target. Reagents are imported and dollar-priced, so a weakening naira raises the cost of a test between one pricing review and the next. A menu set on last year’s cost is already underwater on its most reagent-heavy tests, and the lab may not know until the margin has gone. Knowing the true, current cost of each test lets the lab reprice promptly and precisely, lifting the prices that FX has undercut while leaving the rest alone, rather than applying a blanket increase that punishes loyal customers and still misses the real problem.
In a market this volatile and this thin on margin, pricing on real cost is not a refinement. It is the difference between a lab that adjusts in time and one that absorbs losses it cannot afford.
See every test priced on its true, current cost, with the real margin in plain view. Book a demo and we will reprice a slice of your menu with you.
Ask most laboratories what a test costs and they will quote the reagent price. But a released result is the sum of many things, and the parts nobody counts are usually the ones eating the margin.
A planned cost tells you what a test should consume. The real stock draws tell you what it did. The gap between them is where a lab finds the money it has been losing without knowing.
Margin rarely leaks evenly. A handful of tests, running far over what they should cost, usually drains more than the rest combined. The trick is finding them before they find your bottom line.
We will tailor a demo to how your hospital, clinic, or lab actually runs, offline behaviour, payments, reporting, and all.